Targeted delivery of therapeutic proteins, cytokines, antibodies, nucleic acid or viruses to specific organs or tissues is one of the most important directions in translational and clinical research.A number of preclinical and clinical studies have demonstrated the efficiency of MSCs to serve as an excellent base for a cell-mediated drug delivery system. A Promising cell-mediated drug delivery system due to their high proliferative capacity, multi-potency, and anti-inflammatory and immunomodulatory properties. Optimal delivery vehicle for transferring microcapsules, containing bioactive material, to facilitate the treatment of cancer and/or inflammatory diseases.

Current medical treatments are focused on reducing the inflammation that triggers the signs and symptoms. It is also aimed at improving long-term prognosis by limiting complications. Anti-inflammatory drugs, such as corticosteroids (prednisone and budesonide) are often used as the first line of treatment, followed by immune system suppressors, such as azathioprine (Azasan, Imuran), and mercaptopurine (Purinethol, Purixan). Other immunosuppressants, such as natalizumab (Tysabri) and vedolizumab (Entyvio) have been selectively used. TNF inhibitors or biologics include infliximab (Remicade), adalimumab (Humira) and certolizumab pegol. Regulatory T cell therapy, as well as stem cells are currently in clinical trials with promising results for severe Crohn's patients

Glioblastoma (GBM) is both the most aggressive and lethal malignant brain tumor in adults and accounts for more than 30% of intracranial tumors. Current standard treatment options for malignant gliomas are multimodal and include surgical resection, postoperative radiotherapy, and concomitant chemotherapy with temozolomide A growing body of preclinical and clinical data suggest that genetically engineered oncolytic viruses may be effective therapeutic agents used in the treatment of malignant gliomas. Oncolytic virus and tumor-targeting immune modulatory therapies have shown synergistic inhibition of malignant gliomas. Oncolytic virus immunotherapy of malignant gliomas has been used in clinical trials. The combination of stem cell carriers with oncolytic virus therapy for gliomas enhances antitumor efficacy.

•A novel skin regenerative therapy based on extracellular vesicles (including exosomes) derived from human Mesenchymal Stem Cells (MSCs), shown considerable immunomodulatory and regenerative potential, due to their unique nucleic acids, proteins and lipid cargo. •Exosomes are extracted from various pro-regenerative cellular sources (umbilical cord, amniotic fluid etc), using proprietary GMP-compatible method and fill-finished according to the specific clinical indication. •Regenerative human stem cells-derived exosomes can be locally administered into the skin via needle-free injections and are applicable to both clinical dermatology, such as scar-free wound healing, and to esthetic regenerative medicine, such as fighting immune skin aging. •Orgenesis is developing a proprietary controlled isolation process of ”pro-regenerative” EVs from various stem cell sources such as adipose or placenta. Skin regeneration and rejuvenation Status-Pre Clinical